findmyKOL
Clinical trialNCT02734004Active, not recruitingPhase 1/PHASE2Interventional

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

SponsorAstraZenecaEnrollment264BreastGastric CancersOvarianSCLC
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Susan Domchek, MD

    Abramson Cancer Center, University of Pennsylvania

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Research Site

    Bordeaux, France

  • Research Site

    Caen, France

  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Dijon, France

  • Research Site

    Marseille, France

  • Research Site

    Nantes, France

  • Research Site

    Paris, France

  • Research Site

    Pierre Benit Cedex, France

  • Research Site

    Toulouse, France

  • Research Site

    Villejuif, France

Israel
  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

  • Research Site

    Ramat Gan, Israel

  • Research Site

    Tel Aviv, Israel

Netherlands
  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Maastricht, Netherlands

  • Research Site

    Nijmegen, Netherlands

  • Research Site

    Rotterdam, Netherlands

  • Research Site

    Utrecht, Netherlands

South Korea
  • Research Site

    Goyang-si, South Korea

  • Research Site

    Seongnam-si, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Switzerland
  • Research Site

    Chur, Switzerland

  • Research Site

    Lausanne, Switzerland

United Kingdom
  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Dundee, United Kingdom

  • Research Site

    Glasgow, United Kingdom

  • Research Site

    Greater London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Newcastle upon Tyne, United Kingdom

  • Research Site

    Sutton, United Kingdom

7 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Mar 2016
Primary completion
17 Sept 2021
Completion
17 Sept 2026
Last update posted
20 Apr 2026
Registered enrollment
264
Registry id
NCT02734004

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-004005-16

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.